220 related articles for article (PubMed ID: 9251881)
21. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
[TBL] [Abstract][Full Text] [Related]
22. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
23. Using aprepitant as secondary antiemetic prophylaxis for cancer patients with cisplatin-induced emesis.
Wu CE; Liaw CC
Support Care Cancer; 2012 Oct; 20(10):2357-61. PubMed ID: 22187110
[TBL] [Abstract][Full Text] [Related]
24. Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis.
Bhatia A; Tripathi KD; Sharma M
Indian J Med Res; 2004 Sep; 120(3):183-93. PubMed ID: 15489556
[TBL] [Abstract][Full Text] [Related]
25. Antiemetic activity of ondansetron in cancer patients receiving non-cisplatin chemotherapy.
Fraschini G
Semin Oncol; 1992 Aug; 19(4 Suppl 10):41-7. PubMed ID: 1387249
[TBL] [Abstract][Full Text] [Related]
26. Ondansetron. Therapeutic use as an antiemetic.
Milne RJ; Heel RC
Drugs; 1991 Apr; 41(4):574-95. PubMed ID: 1711961
[TBL] [Abstract][Full Text] [Related]
27. [Use of ondansetron, a 5-HT3 receptor antagonist, as a new type of antiemetic in pediatric oncology].
Csáki C; Ferencz T; Koós R; Schuler D; Borsi J
Orv Hetil; 1993 Jun; 134(25):1363-7. PubMed ID: 8332356
[TBL] [Abstract][Full Text] [Related]
28. Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists.
Hesketh PJ
Support Care Cancer; 1994 Sep; 2(5):286-92. PubMed ID: 8000724
[TBL] [Abstract][Full Text] [Related]
29. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research.
Support Care Cancer; 2000 May; 8(3):229-32. PubMed ID: 10789965
[TBL] [Abstract][Full Text] [Related]
30. Delayed emesis following anticancer chemotherapy.
Kris MG; Pisters KM; Hinkley L
Support Care Cancer; 1994 Sep; 2(5):297-300. PubMed ID: 8000726
[TBL] [Abstract][Full Text] [Related]
31. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
Kris MG; Tyson LB; Clark RA; Gralla RJ
Cancer; 1992 Aug; 70(4 Suppl):1012-6. PubMed ID: 1386282
[TBL] [Abstract][Full Text] [Related]
32. Antiemetics in cancer chemotherapy: historical perspective and current state of the art.
Tonato M; Roila F; Del Favero A; Ballatori E
Support Care Cancer; 1994 May; 2(3):150-60. PubMed ID: 8032700
[TBL] [Abstract][Full Text] [Related]
33. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
34. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
35. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research.
J Clin Oncol; 1998 Sep; 16(9):2937-42. PubMed ID: 9738561
[TBL] [Abstract][Full Text] [Related]
36. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
37. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy.
Italian Group for Antiemetic Research
N Engl J Med; 2000 May; 342(21):1554-9. PubMed ID: 10824073
[TBL] [Abstract][Full Text] [Related]
38. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Hesketh PJ; Van Belle S; Aapro M; Tattersall FD; Naylor RJ; Hargreaves R; Carides AD; Evans JK; Horgan KJ
Eur J Cancer; 2003 May; 39(8):1074-80. PubMed ID: 12736106
[TBL] [Abstract][Full Text] [Related]
39. Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone-lorazepam in the control of cisplatin induced emesis.
Manusirivithaya S; Chareoniam V; Isariyodom P; Sungsab D
J Med Assoc Thai; 2001 Jul; 84(7):966-72. PubMed ID: 11759977
[TBL] [Abstract][Full Text] [Related]
40. [Clinical studies of oral antiemetic drugs on delayed emesis induced by cancer chemotherapy].
Sawaguchi K; Yabushita H; Tsukada H; Yamada H; Noguchi M; Nakanishi M
Gan To Kagaku Ryoho; 1999 Jan; 26(1):117-23. PubMed ID: 9987507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
